Anavex Life Sciences (AVXL) Cash from Operations (QoQ) (2010 - 2025)
Anavex Life Sciences (AVXL) Cash from Operations (QoQ) (2010 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,440.76 Bn | 66,440.47 Bn | - |
| 2 | Nanobiotix | 1,909.20 Bn | 1,909.14 Bn | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - |
| 4 | BeOne Medicines | 468.28 Bn | 463.49 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.49 Bn | 115.24 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.26 Bn | 61.51 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.88 Bn | 62.88 Bn | - |
| 8 | Argenx Se | 55.67 Bn | 50.48 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.37 Bn | 34.36 Bn | 959.66 Mn |
| 10 | Anavex Life Sciences | 222.57 Mn | 90.82 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 16.89% |
| Sep 30, 2025 | 30.97% |
| Jun 30, 2025 | -112.84% |
| Mar 31, 2025 | 51.68% |
| Dec 31, 2024 | -82.04% |
| Sep 30, 2024 | -28.53% |
| Jun 30, 2024 | 55.56% |
| Mar 31, 2024 | -59.28% |
| Dec 31, 2023 | -25.12% |
| Sep 30, 2023 | 23.57% |
| Jun 30, 2023 | 9.85% |
| Mar 31, 2023 | -46.51% |
| Dec 31, 2022 | -43.27% |
| Sep 30, 2022 | 42.67% |
| Jun 30, 2022 | 26.83% |
| Mar 31, 2022 | -175.34% |
| Dec 31, 2021 | 54.38% |
| Sep 30, 2021 | -2.05% |
| Jun 30, 2021 | -2.79% |
| Mar 31, 2021 | 7.04% |